We are presenting a topic research study focused on recent advances in radiation medical countermeasures. Unfortunately, the unstable geo-political situation makes this field very current. The majority of the articles deal with the mitigation of ARS. You can start your reading with a review of radioprotective agents summarizing the repurposing approach of previously approved pharmaceuticals (Singh and Seed).
A couple of original articles are engaged with the application of growth factors in rodent models such as IGF-1 treatment for mitigating GIT damage (Pejchal et al.) and an effective combination of pegylated G-CSF and ghrelin (Kiang et al.). Another group applied a polypharmaceutical approach of pegylated triple combination (hG-SCF, mMG-CSF, and hIL-11), and they even potentiated the effect by combination with lisinopril (Gasperetti et al.). Interestingly, lisinopril was studied by Medhora et al., who proposed that radiation increases its bioavailability by vascular regression.
Other authors showed that survival and hematopoietic recovery can be supported by gamma-tocotrienol (Kumar et al.) and in the case of thoracic irradiation, by hyaluronic nanoparticles (Lierova et al.) or RRx-001 (glucose 6-phosphate dehydrogenase inhibitor; Jurgensen et al.). Additionally, Nanduri et al. evaluated the radioprotective potential of secretory extracellular vesicles as it is seen that a plethora of new radioprotective agents is getting forward to regulatory approval.
Two other overview articles bring interesting radiobiological insights. The review of François et al. discussed the possibility to modulate the inflammatory storm associated with COVID-19 pulmonary infection by exposing patients to ionizing radiation at very low doses. Hollingsworth et al. addressed animal model considerations for designing studies and the potential to use the microbiome as a biomarker to assess radiation exposure and predict the outcome.
Last but not least, we would like to draw your attention to further articles on internal contamination (Griffiths et al.), which compared local and systemic DTPA treatment regimens in vivo, and on a novel panel of radiation-responsive biomarkers, which applied an innovative high-throughput proteomics screening approach (Sproull et al.). Finally, Hermann et al. studied the effect of bardoxolone-methyl and successfully radiosensitized oral squamous cancer cells.
As it is seen, our field makes continuous progress forward, and this topic research comprises the latest advances. We hope you will find these articles interesting and the Editorial team wishes you an inspiring tour into the current radiation medical countermeasures.
Statements
Author contributions
AT drafted the manuscript. AT, DR, LC, and CB edited the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
radioprotection, ionizing radiation (IR), growth factors, medical countermeasure, acute radiation syndrome (ARS)
Citation
Tichy A, Ricobonno D, Cary LH and Badie C (2022) Editorial: Recent advances in radiation medical countermeasures. Front. Pharmacol. 13:983702. doi: 10.3389/fphar.2022.983702
Received
01 July 2022
Accepted
18 July 2022
Published
13 September 2022
Volume
13 - 2022
Edited and reviewed by
Alastair George Stewart, The University of Melbourne, Australia
Updates
Copyright
© 2022 Tichy, Ricobonno, Cary and Badie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ales Tichy, ales.tichy@unob.cz
This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.